CA2719115A1 - Methods, dosage forms, and kits for administering ziprasidone without food - Google Patents

Methods, dosage forms, and kits for administering ziprasidone without food Download PDF

Info

Publication number
CA2719115A1
CA2719115A1 CA2719115A CA2719115A CA2719115A1 CA 2719115 A1 CA2719115 A1 CA 2719115A1 CA 2719115 A CA2719115 A CA 2719115A CA 2719115 A CA2719115 A CA 2719115A CA 2719115 A1 CA2719115 A1 CA 2719115A1
Authority
CA
Canada
Prior art keywords
ziprasidone
dosage form
human
solid oral
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2719115A
Other languages
English (en)
French (fr)
Inventor
William John Curatolo
Scott Max Herbig
Avinash Govind Thombre
Jaymin Chandrakant Shah
Sheri L. Shamblin
Timothy Lukas
William Brett Caldwell
Dwayne Thomas Friesen
David Keith Lyon
Christopher Donovan Craig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2719115A1 publication Critical patent/CA2719115A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2719115A 2008-03-07 2009-03-04 Methods, dosage forms, and kits for administering ziprasidone without food Abandoned CA2719115A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3494708P 2008-03-07 2008-03-07
US61/034,947 2008-03-07
PCT/IB2009/000442 WO2009109844A1 (en) 2008-03-07 2009-03-04 Methods, dosage forms, and kits for administering ziprasidone without food

Publications (1)

Publication Number Publication Date
CA2719115A1 true CA2719115A1 (en) 2009-09-11

Family

ID=40720011

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2719115A Abandoned CA2719115A1 (en) 2008-03-07 2009-03-04 Methods, dosage forms, and kits for administering ziprasidone without food

Country Status (15)

Country Link
US (1) US20110002989A1 (https=)
EP (1) EP2280711A1 (https=)
JP (1) JP2009215293A (https=)
KR (1) KR20100131477A (https=)
CN (1) CN102014910A (https=)
AR (1) AR070964A1 (https=)
AU (1) AU2009220925A1 (https=)
BR (1) BRPI0909818A2 (https=)
CA (1) CA2719115A1 (https=)
IL (1) IL207792A0 (https=)
MX (1) MX2010009844A (https=)
RU (1) RU2010135831A (https=)
TW (1) TW200950783A (https=)
WO (1) WO2009109844A1 (https=)
ZA (1) ZA201005905B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
US9510148B2 (en) * 2009-03-03 2016-11-29 Mobilitie, Llc System and method for wireless communication to permit audience participation
CN105492007A (zh) * 2013-05-03 2016-04-13 欣达克斯制药公司 癌症治疗方法
CA2919522C (en) 2013-07-30 2019-02-26 Gilead Connecticut, Inc. Formulation of syk inhibitors
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
EP3076951B1 (en) * 2013-12-05 2020-09-30 Celal Albayrak Process for the production of drug formulations for oral administration
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US10474345B2 (en) * 2014-04-04 2019-11-12 Shawn SHEY User interfaces and methods for displaying content
RU2017106029A (ru) * 2014-09-19 2018-10-19 Дзе Проктер Энд Гэмбл Компани Способ изготовления ядра частиц, содержащего покрытие активным веществом
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US11154510B2 (en) 2015-06-11 2021-10-26 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CN107714669A (zh) * 2016-08-11 2018-02-23 广东东阳光药业有限公司 齐拉西酮缓释剂及其制备方法
CA3073871A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. Polymorphs of syk inhibitors
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
CA2613474A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds

Also Published As

Publication number Publication date
US20110002989A1 (en) 2011-01-06
WO2009109844A1 (en) 2009-09-11
JP2009215293A (ja) 2009-09-24
IL207792A0 (en) 2010-12-30
BRPI0909818A2 (pt) 2015-10-06
ZA201005905B (en) 2011-11-30
AU2009220925A1 (en) 2009-09-11
EP2280711A1 (en) 2011-02-09
MX2010009844A (es) 2010-09-30
RU2010135831A (ru) 2012-04-20
KR20100131477A (ko) 2010-12-15
TW200950783A (en) 2009-12-16
AR070964A1 (es) 2010-05-19
CN102014910A (zh) 2011-04-13

Similar Documents

Publication Publication Date Title
US20110002989A1 (en) Methods, dosage forms and kits for administering ziprasidone without food
US12447128B2 (en) Formulations of enzalutamide
US20070190129A1 (en) Sustained release dosage forms of ziprasidone
JP2011516613A (ja) 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
JP2025134801A (ja) オラパリブの溶解度及び生体利用効率が改善された組成物
EP2540318A1 (en) Sustained-release solid preparation for oral use
HK1150392A (en) Methods, dosage forms, and kits for administering ziprasidone without food
HK40108713A (en) Formulations of enzalutamide
HK40116766A (en) Formulations of enzalutamide
HK40065232A (en) Formulations of enzalutamide
HK40037883A (en) Formulations of enzalutamide
HK40037883B (en) Formulations of enzalutamide

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130805